Allogene Therapeutics Inc Live Stock Price Today, Share Analysis and Chart

Name: Allogene Therapeutics Inc: Is Infosys Ltd. worth buying?
Item: Allogene Therapeutics Inc
Rating: 1.55691675
Author: Trendlyne DVM scores

about

Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf"...

2.00 -0.14 (-6.54%)

55.16% Fall from 52W High

7.7M

XNAS Volume

XNAS 15 May, 2026 5:30 PM (EDT)

Not Eligible

Expensive Valuation

9.2 / 100

Technically Neutral

53.1 / 100

1Yr Price target upside is 274%

12 analysts

Allogene Therapeutics Inc Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Allogene Therapeutics Inc Live Stock Price Today, Share Analysis and Chart

Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf"...

55.16% Fall from 52W High

SWOT Analysis

Allogene Therapeutics Inc Live Price Chart